Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

Journal of Clinical Pharmacology

Volumn 44, Issue 6, 2004, Pages 590-598

  Dowell, James A ^a   Knebel, William ^b   Ludden, Tom ^b   Stogniew, Marty ^a   Krause, David ^a   Henkel, Tim ^a  

^a Vicuron Pharmaceuticals   (United States)

^b ICON Development Solutions   (United States)

Author keywords

Anidulafungin; Clearance; Echinocandin antifungal; Pharmacokinetics

Indexed keywords

ANIDULAFUNGIN; CYTOCHROME P450; PYRROLE; RIFAMPICIN;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; BODY WEIGHT; CANDIDIASIS; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; ESOPHAGUS CANDIDIASIS; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POPULATION MODEL; POPULATION RESEARCH; STEADY STATE; THRUSH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CANDIDIASIS; CONTINENTAL POPULATION GROUPS; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PEPTIDES, CYCLIC; SEX FACTORS;

EID: 2442695447     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004265644     Document Type: Article

References (12)

1. Chiou CC, Groll AH, Walsh TJ: New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000;5(2):120-135.
2. Serrano Mdel C, Valverde-Conde A, Chavez MM, Bernal S, Claro RM, Peman J, et al: In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin and amphotericin B against Aspergillus spp. Diagn Microbiol Infect Dis 2003;45(2):131-135.
3. Arevalo MP, Carrillo-Munoz AJ, Salgado J, Cardenes D, Brio S, Quindos G, et al: Antifungal activity of the echinocandin anidulafungin against yeast pathogens: a comparative study with M27-A microdilution method. J Antimicrob Chemother 2003;51(1):163-166.
4. Moore CB, Oakley KL, Denning DW: In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001;7(1):11-16.
5. Bartlett MS, Current WL, Goheen MP, Boylan CJ, Lee CH, Shaw MM, et al: Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother 1996;40(8):1811-1816.
6. Brown GL, White RJ, Taubel J: Phase 1 dose optimization study for V-echinocandin [poster 1105]. Poster presented at the 40th Annual ICAAC Conference, Toronto, September 2000.
7. Thye D, Shepherd B, White RJ, Weston IE, Henkel T: Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers [poster 36]. Poster presented at the 41st Annual ICAAC Conference, Chicago, December 2001.
8. Stogniew M, Pu F, Henkel T, Dowell J: Anidulafungin biotransformation in humans is by degradation not metabolism. Clin Microbiol Infect 2003;9(Suppl.):291.
9. Dowell J, Stogniew M, Krause D: Anidulafungin dosage adjustments are not required for patients with hepatic and/or renal impairment. Clin Microbiol Infect 2003;9(Suppl.):290-291.
10. Flockhart DA: Drugs metabolized by known P450's [reference list]. Indiana School of Medicine, January 2002. Retrieved from http://medicine.iupui.edu/flockhart/
11. Beal SL, Sheiner LB (eds.): NONMEM Users Guides: Parts I-VIII. Hanover, MD: GloboMax LLC, 1988-1998.
12. Jonnson EN, Karlsson MO: Xpose 2.0 User's Manual. Sweden: Uppsala University, Department of Pharmacy, 1997.